Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration
Clinical trial NCT01033721 · COMPLETED
Trial details
- NCT number
- NCT01033721
- Sponsor
- Paloma Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2010-06-01
- Primary completion
- 2011-12-01
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.